1. In Vivo
  2. >>Market Intelligence

Israeli Biopharma Leaders Focus On Near-Term Targets

 
• By David Wild

Biopharma executives in Israel rely on their global footprint and a 'culture of resilience'.  

Israeli Biopharma CEOs Say Programs And Operations On Track • Source: Shutterstock

Israel is well known for punching above its weight in biopharma, with the country’s industry bringing innovation to the sector. In Vivo has spoken to industry leaders there to understand the impact of the turbulent climate triggered by Hamas’s 7 October attacks on Israel. Biopharma executives say that having operations dispersed globally and relying on a “cultural resilience” have helped limit the knock-on effects on the industry.

Anat Cohen-Dayag, president and CEO of Compugen Ltd., told In Vivo that after the attacks on 7 October, she...

More from Market Intelligence

More from In Vivo

Geopolitical Volatility Not Dimming A Healthy Mid-Term Outlook For Life Sciences Deals

 
• By Ashley Yeo

New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.

Navigating the GLP-1 Opportunity In China: Strategic Imperatives For Western Pharma

 
• By Jo Shorthouse

The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.

Strategic Surprises: The Drugs That Rewrote The Forecasts

 
• By Edwin Elmhirst

Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.